Evidence map›Paper›PMID 33129330›Full record

ArticleJournal of nanobiotechnology2020

Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p.

Lei Zhuang, Wenzheng Xia, Didi Chen, Yijia Ye, Tingting Hu, Shiting Li, Meng Hou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 117 citations in OpenAlex.

  1. Article
  2. Review
  3. Extracellular vesicles and epigenetic aging clocks in tissue aging: an exosome-focused conceptual framework with a focus on skin.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Lei ZhuangDepartment of Hepatobiliary Surgery, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Wenzheng XiaDepartment of Neurosurgery, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Didi ChenDepartment of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, People's Republic of China.
Yijia YeDepartment of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, People's Republic of China.
Tingting HuDepartment of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, People's Republic of China.
Shiting LiDepartment of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China. lishiting@xinhuamed.com.cn.
Meng HouDepartment of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325000, People's Republic of China. 244517813@qq.com.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNXinHua Hospital · CN

Funding

Key Programme 81671205Key Programme 81974186the National Natural Science Foundation of China 82071561
6 · The paper itself

Abstract

backgroundThe chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosome

resultsExosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome

conclusionsThe results indicated exosome

Indexed as

AnimalsCardiotoxicityDoxorubicinExosomesGene Expression RegulationHeart InjuriesHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMesenchymal Stem CellsMiceMicroRNAsMyocytes, CardiacRNA, Long NoncodingSignal TransductionDoxorubicinIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMicroRNAsMIF protein, humanMIR221, humanNEAT1 long non-coding RNA, humanRNA, Long NoncodingSIRT2 protein, humanSirtuin 2Doxorubicin-induced cardiomyopathyExosomeLncRNA-NEAT1/miR-221-3p/Sirt2 signaling pathwayMacrophage migration inhibitory factor (MIF)Mesenchymal stem cells

Identifiers

PMID33129330
PMCPMC7603694
OpenAlexW3097675828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.